The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 04, 2013
Filed:
May. 28, 2010
John J. Baldwin, Gwynedd, PA (US);
David A. Claremon, Maple Glen, PA (US);
Colin M. Tice, Maple Glen, PA (US);
Salvacion Cacatian, Philadelphia, PA (US);
Lawrence W. Dillard, Yardley, PA (US);
Alexey V. Ishchenko, Elkins Park, PA (US);
Jing Yuan, Lansdale, PA (US);
Zhenrong Xu, Horsham, PA (US);
Gerard Mcgeehan, Garnet Valley, CA (US);
Wei Zhao, Eagleville, PA (US);
Robert D. Simpson, Wilmington, DE (US);
Suresh B. Singh, Kendall Park, NJ (US);
Patrick T. Flaherty, Pittsburgh, PA (US);
Jean-pierre Wery, Indianapolis, IN (US);
John J. Baldwin, Gwynedd, PA (US);
David A. Claremon, Maple Glen, PA (US);
Colin M. Tice, Maple Glen, PA (US);
Salvacion Cacatian, Philadelphia, PA (US);
Lawrence W. Dillard, Yardley, PA (US);
Alexey V. Ishchenko, Elkins Park, PA (US);
Jing Yuan, Lansdale, PA (US);
Zhenrong Xu, Horsham, PA (US);
Gerard McGeehan, Garnet Valley, CA (US);
Wei Zhao, Eagleville, PA (US);
Robert D. Simpson, Wilmington, DE (US);
Suresh B. Singh, Kendall Park, NJ (US);
Patrick T. Flaherty, Pittsburgh, PA (US);
Jean-Pierre Wery, Indianapolis, IN (US);
Vitae Pharmaceuticals, Inc., Fort Washington, PA (US);
Abstract
Diaminoalkanes of below Formula I have now been found which are orally active and bind to aspartic proteases to inhibit their activity: They are useful in the treatment or amelioration of diseases associated with elevated levels of aspartic protease activity. The invention also relates to a method for the use of the compounds of Formula I in ameliorating or treating aspartic protease related disorders in a subject in need thereof comprising administering to said subject an effective amount of a compound of Formula I.